Vir acquires antiviral gene-editing biotech Agenovir

Antiviral company Agenovir Corp. is now part of Vir Biotechnology Inc. (San Francisco, Calif.) under a "recent acquisition", according to a Vir spokesperson. Terms of the deal were unavailable through the Vir spokesperson.

Agenovir has developed CRISPR-based gene editing technology to eliminate latent viral reservoirs in viral DNA, with an initial developmental program in HPV...